A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
Clinical trial NCT05063162 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05063162
- Sponsor
- UCB Biopharma SRL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-02
- Primary completion
- 2027-05-06
- Enrollment
- 113
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.